A Clinical Study of Children with SIL-TAL1-Positive Acute T-Lymphoblastic Leukemia.
10.19746/j.cnki.issn.1009-2137.2025.05.004
- Author:
Yu-Juan XUE
1
;
Yu WANG
1
;
Le-Ping ZHANG
1
;
Ai-Dong LU
1
;
Yue-Ping JIA
1
;
Hui-Min ZENG
1
Author Information
1. Department of Pediatrics, Peking University People's Hospital, Beijing 100044, China.
- Publication Type:Journal Article
- Keywords:
acute T-lymphoblastic leukemia;
children
- MeSH:
Humans;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis*;
Prognosis;
Child;
Male;
Female;
Survival Rate;
T-Cell Acute Lymphocytic Leukemia Protein 1;
Child, Preschool;
Oncogene Proteins, Fusion;
Leukocyte Count
- From:
Journal of Experimental Hematology
2025;33(5):1262-1268
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the clinical characteristics and prognosis of children with SIL-TAL1-positive T-cell acute lymphoblastic leukemia ( SIL-TAL1+ T-ALL).
METHODS:The clinical data of 110 children with newly diagnosed T-ALL admitted to the pediatric department of our hospital from January 2010 to December 2018 were reviewed to compare the clinical characteristics, treatment response and prognosis between SIL-TAL1+ group and SIL-TAL1-group.
RESULTS:Among the 110 children with T-ALL, 25 cases (22.7%) were in the SIL-TAL1+ group and 85 cases (77.3%) in the SIL-TAL1- group. The white blood cell (WBC) count in the SIL-TAL1+ group was significantly higher than that in the SIL-TAL1- group (P < 0.05), while the other clinical characteristics and treatment response were not significantly different between the two groups. The 5-year overall survival (OS) rates of SIL-TAL1+ group and SIL-TAL1- group were 80.0% and 75.5%, and 5-year disease-free survival (DFS) rates were 76.0% and 72.9%, respectively. There were no significant differences in OS rate and DFS rate between the two groups ( P >0.05). In children aged < 10 years, the 5-year OS rate of SIL-TAL1+ group and SIL-TAL1- group was 100% and 75.1%, respectively, and the difference between the two groups was statistically significant (P < 0.05).
CONCLUSION:Although the WBC level is significantly higher in children with SIL-TAL1+ T-ALL than that in those with SIL-TAL1- T-ALL, the treatment efficacy is similar between the two groups. In children aged < 10 years, the longterm survival rate is superior in the SIL-TAL1+ group.
